A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.

CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.

CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.

Placebo will be adminstered subcutaneously as per the appropriate randomized arm.

Stable dose of methotrexate will be maintained through Week 24.